| Active substance | Finerenone |
| Holder | Bayer AG |
| Status | Running |
| Indication | Chronic Kidney Disease in pediatric patients who participated in the FIONA open label extension study. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 23/07/2025 |